First Tracks Biotherapeutics is trading 12.22% up at $46.20, based on the provided live price context, with no confirmed catalyst identified. - No clear company-specific announcement dated September 2, 2026, was identified. - Its latest release, dated August 26, announced investor conferences on September 9, 10, and 16, but no new clinical, financial, or regulatory catalyst. - Broader markets are mixed, so macro sentiment does not clearly explain the gain; volume information was unavailable.